Jefferies analyst Gena Wang reiterates Buy rating and $109 price target on Ultragenyx Pharmaceuticals (NASDAQ: RARE), noting clinical progress across ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE